Fda

ER-100 FDA Clearance | First Human Trial of Partial Epigenetic Reprogramming for Optic Neuropathies

Life Biosciences receives IND clearance on January 28, 2026 for the first-ever human clinical trial of AAV2-delivered OSK Yamanaka factors targeting retinal ganglion cell rejuvenation in glaucoma and NAION

William Rodriguez · Jan 28, 2026